These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 16638874)
41. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983 [TBL] [Abstract][Full Text] [Related]
42. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Hou G; Zhang Q; Wang L; Liu M; Wang J; Xue L Cancer Lett; 2010 Apr; 290(2):248-54. PubMed ID: 19853373 [TBL] [Abstract][Full Text] [Related]
43. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE Oncogene; 2001 Apr; 20(16):2044-9. PubMed ID: 11360188 [TBL] [Abstract][Full Text] [Related]
44. Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. De Angel RE; Smith SM; Glickman RD; Perkins SN; Hursting SD Nutr Cancer; 2010; 62(8):1074-86. PubMed ID: 21058195 [TBL] [Abstract][Full Text] [Related]
45. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice. van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875 [TBL] [Abstract][Full Text] [Related]
46. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oakes SR; Robertson FG; Kench JG; Gardiner-Garden M; Wand MP; Green JE; Ormandy CJ Oncogene; 2007 Jan; 26(4):543-53. PubMed ID: 16862169 [TBL] [Abstract][Full Text] [Related]
47. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886 [TBL] [Abstract][Full Text] [Related]
49. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Liu R; Varghese S; Rabkin SD Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042 [TBL] [Abstract][Full Text] [Related]
50. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Nogueira LM; Dunlap SM; Ford NA; Hursting SD Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497 [TBL] [Abstract][Full Text] [Related]
51. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. Ip C; Ip MM; Loftus T; Shoemaker S; Shea-Eaton W Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):689-96. PubMed ID: 10919739 [TBL] [Abstract][Full Text] [Related]
52. Effects of intermittent and chronic calorie restriction on mammalian target of rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and mammary tumors. Dogan S; Johannsen AC; Grande JP; Cleary MP Nutr Cancer; 2011; 63(3):389-401. PubMed ID: 21462085 [TBL] [Abstract][Full Text] [Related]
53. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin. Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175 [TBL] [Abstract][Full Text] [Related]
54. TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen. Heffelfinger SC; Gear RB; Schneider J; LaDow K; Yan M; Lu F; Pyle AL; Warshawsky D Lab Invest; 2003 Jul; 83(7):1001-11. PubMed ID: 12861040 [TBL] [Abstract][Full Text] [Related]
55. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253 [TBL] [Abstract][Full Text] [Related]
56. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S Cancer Res; 2003 Aug; 63(15):4384-8. PubMed ID: 12907608 [TBL] [Abstract][Full Text] [Related]
57. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mosley JD; Poirier JT; Seachrist DD; Landis MD; Keri RA Mol Cancer Ther; 2007 Aug; 6(8):2188-97. PubMed ID: 17699716 [TBL] [Abstract][Full Text] [Related]
58. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions. Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487 [TBL] [Abstract][Full Text] [Related]
59. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075 [TBL] [Abstract][Full Text] [Related]
60. Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats. Davies BR; Warren JR; Schmidt G; Rudland PS Biochem Soc Symp; 1998; 63():167-84. PubMed ID: 9513721 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]